MolProbity Ramachandran analysis

MolProbity Ramachandran analysis
2EIN, model 1
General case
180
N
A
Isoleucine and valine
180
SER
99 SER
O 89
89 GLU
GLU
B
Psi
O
W
J 15
59
15ASP
GLN
ASP
Psi
PC 3838ASN
ASN
10ASN
ASN
G 54 ARG UH 10
A 369 ASP
0
G
T
4 ALA
U 8 ILE
H 8 ILE
0
TG 88HIS
HIS
BO 60
60GLU
GLU
O 202 SER
Y 28 PHE
GT 77ASP
ASP
FS 96
96 LEU
LEU
GT 33 ALA
ALA
F S 9595
GLN
GLN
G
T 39
39 SER
SER
A 91
91 ASP
ASP
N
O 159 VAL
S 94 HIS
F 94 HIS
-180
-180
0
Phi
-180
180
Pre-proline
180
-180
0
Phi
180
Glycine
180
T 40 GLY
G
Psi
Psi
B
O 92
92 ASN
ASN
0
296GLY
GLY
U
HN 47
47
GLY
0
G
T
-180
66 GLY
GLY
-180
-180
0
Phi
180
Trans proline
180
-180
Psi
Phi
180
Phi
180
Cis proline
180
F 93 PRO
S
0
Psi
T 49 PRO
0
0
A 174 PRO
-180
-180
-180
91.4% (3204/3504) of all residues were in favored (98%) regions.
98.5% (3453/3504) of all residues were in allowed (>99.8%) regions.
There were 51 outliers (phi, psi):
A 9 SER (-41.6, 157.4)
A 91 ASP (-177.6, -157.7)
A 174 PRO (-34.3, -32.8)
A 369 ASP (47.5, 14.6)
B 60 GLU (169.8, -37.9)
B 89 GLU (-23.6, 138.4)
B 92 ASN (61.5, 94.8)
C 38 ASN (34.6, 77.4)
F 93 PRO (-35.0, 175.8)
F 94 HIS (29.5, -178.2)
F 95 GLN (86.5, -102.6)
F 96 LEU (61.3, -82.3)
G 3 ALA (84.9, -95.5)
G 4 ALA (171.2, 16.1)
G 6 GLY (-176.1, -54.7)
G 7 ASP (4.1, -98.8)
G 8 HIS (52.1, -21.2)
G 39 SER (-63.0, -120.9)
G 40 GLY (65.2, 129.0)
G 54 ARG (34.3, 39.1)
H 8 ILE (81.4, 3.0)
H 10 ASN (91.7, 41.0)
H 47 GLY (64.2, 84.3)
0
J
N
N
N
O
O
O
O
O
O
P
S
S
S
S
T
T
T
T
T
T
T
T
U
U
U
W
Y
Phi
180
-180
0
15 ASP (-64.0, 86.7)
9 SER (-39.7, 160.1)
91 ASP (-179.1, -158.7)
296 GLY (67.3, 85.8)
59 GLN (-64.0, 86.7)
60 GLU (172.1, -40.9)
89 GLU (-23.6, 139.3)
92 ASN (61.6, 94.7)
159 VAL (-87.4, -165.4)
202 SER (-29.1, -44.6)
38 ASN (29.9, 78.6)
93 PRO (-34.4, 174.4)
94 HIS (10.5, -169.5)
95 GLN (94.2, -106.0)
96 LEU (62.2, -84.9)
3 ALA (87.5, -98.2)
4 ALA (171.2, 16.2)
6 GLY (-174.8, -58.2)
7 ASP (9.6, -102.1)
8 HIS (49.8, -18.1)
39 SER (-61.4, -124.3)
40 GLY (65.7, 129.7)
49 PRO (-59.4, 53.6)
8 ILE (78.9, 10.3)
10 ASN (88.9, 42.9)
47 GLY (63.3, 84.2)
15 ASP (-63.6, 86.1)
28 PHE (-61.1, -76.9)
http://kinemage.biochem.duke.edu
Lovell, Davis, et al. Proteins 50:437 (2003)